Asset
Mitapivat
Agios Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02108106 | phase1 | completed | 2014-03-01 | 2014-08-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT02149966 | phase1 | completed | 2014-05-01 | 2014-11-01 | Agios Pharmaceuticals, Inc. | A Phase I Study of AG-348 in Healthy Volunteers |
| NCT03559699 | phase3 | completed | 2018-06-26 | 2020-11-12 | Agios Pharmaceuticals, Inc. | A Study Evaluating the Efficacy and Safety of AG-348 in Regularly Transfused Adult Participants With Pyruvate Kinase Deficiency (PKD) |
| NCT02476916 | phase2 | completed | 2015-06-26 | 2017-05-08 | Agios Pharmaceuticals, Inc. | A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) Deficiency |
| NCT03692052 | phase2 | active_not_recruiting | 2019-03-20 | 2020-08-20 | Agios Pharmaceuticals, Inc. | A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia |
FDA applications (0)
This company has no applications containing this asset.